Importantly, as the pharmacological inhibition of PDK1 or ROCK reduces motor impairment, lowers brain PrPSc and Aβ levels, and prolongs the lifespan of prion-infected mice, PDK1 and ROCK are currently considered as potential therapeutic targets to combat prion diseases (Pietri et al., 2013; Alleaume-Butaux et al., 2015; Ezpeleta et al., 2019). The gene discussed is PDK1; the disease is prion disease.